Phase II Trial Compares Telemedicine vs In-Person Buprenorphine Treatment for Opioid Use Disorder — Addressing Treatment Access Barriers

References

1. 1.Huskamp, H. A., Busch, A. B., Souza, J., Uscher-Pines, L., Rose, S., Wilcock, A., ... & Mehrotra, A. (2018). How is telemedicine being used in opioid and other substance use disorder treatment? Health Affairs, 37(12), 1940-1947. https://doi.org/10.1377/hlthaff.2018.0134
2. 2.New York State Psychiatric Institute. (2024). A randomized, controlled trial of sublingual buprenorphine through telemedicine vs in-person care as usual in the treatment of opioid use disorder. ClinicalTrials.gov. NCT05339256. https://clinicaltrials.gov/study/NCT05339256
3. 3.Samples, H., Williams, A. R., Olfson, M., & Crystal, S. (2018). Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. Journal of Substance Abuse Treatment, 95, 9-17. https://doi.org/10.1016/j.jsat.2018.04.009
4. 4.Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006). SAMHSA. https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-nnr.pdf
5. 5.Uscher-Pines, L., Sousa, J., Raja, P., Mehrotra, A., Barnett, M. L., & Huskamp, H. A. (2020). Suddenly becoming a 'virtual doctor': experiences of psychiatrists transitioning to telemedicine during the COVID-19 pandemic. Psychiatric Services, 72(1), 48-54. https://doi.org/10.1176/appi.ps.202000250